Filtered By:
Condition: Diabetes
Drug: Aspirin

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 378 results found since Jan 2013.

Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians
Conclusion These results highlight that CYP2C19*2, along with diabetes, and use of proton pump inhibitor and statin are important factors jointly associated with variability in clinical response to DAPT following ACS in Egyptians.
Source: Pharmacogenetics and Genomics - September 1, 2018 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
This study is registered with ClinicalTrials.gov, number NCT00501059.FindingsBetween July 5, 2007, and Nov 15, 2016, 12 546 patients were enrolled and randomly assigned to receive aspirin (n=6270) or placebo (n=6276) at 501 study sites. Median follow-up was 60 months. In the intention-to-treat analysis, the primary endpoint occurred in 269 (4·29%) patients in the aspirin group versus 281 (4·48%) patients in the placebo group (hazard ratio [HR] 0·96; 95% CI 0·81–1·13; p=0·6038). Gastrointestinal bleeding events (mostly mild) occurred in 61 (0·97%) patients in the aspirin group versus 29 (0·46%) in the placebo gr...
Source: The Lancet - August 27, 2018 Category: General Medicine Source Type: research

Studies: Low-Dose Aspirin May Not Prevent Initial Heart Attack, Stroke
Taking a low-dose aspirin every day has long been known to cut the chances of another heart attack, stroke or other heart problem in people who already have had one, but the risks don’t outweigh the benefits for most other folks, major new research finds. Although it’s been used for more than a century, aspirin’s value in many situations is still unclear. The latest studies are some of the largest and longest to test this pennies-a-day blood thinner in people who don’t yet have heart disease or a blood vessel-related problem. One found that aspirin did not help prevent first strokes or heart attacks...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 27, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch aspirin Source Type: news

Association Between Proton Pump Inhibitor Use and Risk of  Stroke
We read with interest the article by Nguyen et  al1 evaluating the association between proton pump inhibitor (PPI) use and ischemic stroke. The authors found that PPI use was associated with a significant increase in the risk of ischemic stroke after adjustment for established risk factors for stroke including smoking status, body mass index, p hysical activity, dietary quality, alcohol use, menopausal hormone use in women, multivitamin use, regular aspirin use, regular nonaspirin nonsteroidal anti-inflammatory drug, use and personal history of hypertension, hyperlipidemia, coronary artery disease, or diabetes.
Source: Gastroenterology - August 6, 2018 Category: Gastroenterology Authors: Cong Dai, Min Jiang, Ming-Jun Sun Tags: Correspondence Source Type: research

Association of early loss of primary functional patency of arteriovenous access with mortality in incident hemodialysis patients: A nationwide population-based observational study
The long-term survival and life quality of hemodialysis (HD) patients depend on adequacy of dialysis via a well-functioning vascular access. Loss of primary functional patency (PFP) of an arteriovenous access (AVA) eventually happens in HD patients. The association between time to loss of PFP of AVAs and mortality in HD patients remains unclear. The retrospective nationwide population-based cohort study compared the hazards of mortality with time to loss of PFP. We enrolled 1618 adult incident HD patients who received HD via AVAs for at least 90 days between January 1, 2001 and December 31, 2013. They were divided into ear...
Source: Medicine - August 1, 2018 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
Publication date: Available online 17 July 2018Source: The LancetAuthor(s): Peter M Rothwell, Nancy R Cook, J Michael Gaziano, Jacqueline F Price, Jill F F Belch, Maria Carla Roncaglioni, Takeshi Morimoto, Ziyah MehtaSummaryBackgroundA one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes.MethodsUsing individual patient data, we analysed the modifying effects of bodyweight (10 kg bands) and height (10 cm ...
Source: The Lancet - July 18, 2018 Category: General Medicine Source Type: research

Patients with atrial fibrillation and coronary artery disease – Double trouble
Publication date: March 2018Source: Advances in Medical Sciences, Volume 63, Issue 1Author(s): Ewelina Michniewicz, Elżbieta Mlodawska, Paulina Lopatowska, Anna Tomaszuk-Kazberuk, Jolanta MalyszkoAbstractCoronary artery disease (CAD) is the most common cardiovascular disease while atrial fibrillation (AF) is the most common cardiac arrhythmia. Both diseases share associated risk factors – hypertension, diabetes mellitus, sleep apnea, obesity and smoking. Moreover, inflammation plays a causative role in both diseases. The prevalence of CAD in patients with AF is from 17% to 46.5% while the prevalence of AF among patients...
Source: Advances in Medical Sciences - July 11, 2018 Category: Biomedical Science Source Type: research

Aspirin lowers risk of death in people with concomitant heart failure and diabetes
Aspirin reduces the risk of  all-cause death or hospitalisation for heart failure in patients with concomitant type 2 diabetes and heart failure but increases the risk of non-fatal heart attack or stroke.
Source: Clinical Pharmacist - June 22, 2018 Category: Drugs & Pharmacology Source Type: research

Risk Scoring System to Assess Outcomes in Patients Treated with Contemporary Guideline-Adherent Optimal Therapies after Acute Myocardial Infarction.
CONCLUSIONS: The KorMI system would be a useful tool for predicting outcomes in survivors treated with guideline-adherent optimal therapies after AMI. PMID: 29856143 [PubMed]
Source: Korean Circulation Journal - June 3, 2018 Category: Cardiology Tags: Korean Circ J Source Type: research

It's reticulated: the liver at the heart of atherosclerosis
Platelets play a critical role in both the initiation and progression of atherosclerosis, and even more so in the ensuing atherothrombotic complications. Low-dose aspirin remains the mainstay of antiplatelet therapy in high-risk patients by reducing the risk of myocardial ischemia, stroke or death due to cardiovascular disease. However, antiplatelet therapies lose their efficacy in people with diabetes mellitus, increasing the risk of future atherothrombotic events. The molecular mechanisms that promote platelet hyperactivity remain unclear but could be due to glycation-induced conformational changes of platelet membranes ...
Source: Journal of Endocrinology - May 29, 2018 Category: Endocrinology Authors: Nagareddy, P. R., Noothi, S. K., Flynn, M. C., Murphy, A. J. Tags: Review Source Type: research

Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke.
Conclusions: CR and END are fairly common after acute IS. CR is associated with higher risk of END. Clopidogrel plus aspirin combination therapy provides greater inhibition of platelet aggregation, and may afford protection against END. PMID: 29731992 [PubMed]
Source: Oncotarget - May 9, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Publication date: Available online 12 March 2018 Source:The Lancet Author(s): Joo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, Deok-Kyu Cho, Jin Bae Lee, Joon-Hyung Doh, Sang-Hyun Kim, Jin-Ok Jeong, Jang-Ho Bae, Byung-Ok Kim, Jang Hyun Cho, Il-Woo Suh, Doo-il Kim, Hoon-Ki Park, Jong-Seon Park, Woong Gil Choi, Wang Soo Lee, Jihoon Kim, Ki Hong Choi, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon Background Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients...
Source: The Lancet - March 13, 2018 Category: General Medicine Source Type: research

Aspirin Linked to Lower Mortality in Diabetes With Heart Failure Aspirin Linked to Lower Mortality in Diabetes With Heart Failure
Researchers were surprised to see a paradoxical increase in nonfatal MI and stroke in parallel with lower mortality with aspirin for primary prevention in patients with diabetes and heart failure.Medscape Medical News
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aspirin lowers risk of death for patients with diabetes, heart failure
(American College of Cardiology) For people living with both Type 2 diabetes and heart failure, taking an aspirin each day appears to lower the risk of dying or being hospitalized for heart failure, according to research being presented at the American College of Cardiology's 67th Annual Scientific Session. But the data also reveal aspirin use may increase the risk of nonfatal heart attack or stroke, a somewhat contradictory finding that surprised researchers.
Source: EurekAlert! - Medicine and Health - February 28, 2018 Category: International Medicine & Public Health Source Type: news